BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Synergy Healthcare plc (SYR): Q1 Interim Management Statement


7/14/2009 11:49:37 AM

Synergy (SYR.L), a leading provider of outsourced healthcare support services in the UK, Continental Europe, Asia and South Africa, is pleased to provide an update on its progress since 29 March 2009.

Overall trading has been in line with the Board’s expectations. Sales in the first quarter increased 9.7% on the same period last year to £72.6 million (Q1 2007/8: £66.2 million). UK sales reflect the planned exit from low margin, non core business lines which masks the continued growth in Decontamination services. Sales in the operating regions were as follows:

Sales Q1 09 Sales Q1 08 Growth

United Kingdom £38.8 million £38.4 million 1.0%

Rest of Europe £31.6 million £25.9 million 22.2%

Asia and South Africa £2.2 million £1.8 million 17.7%

As reported in June, Synergy continues to see improvements in its net operating margins and remains on course to have these fully restored by the autumn of this year.

Net debt reduced in the quarter by £17 million to £153 million (28 March 2009: £170 million) reflecting a net generation of free cash of £10 million together with favourable translation of the Euro and Chinese Yuan debt into Sterling. The debt position remains comfortably within covenants agreed with the Company’s syndicate of banks.

Richard Steeves, Chief Executive of Synergy, said: “The business has had a very positive start to the year and, with a number of new decontamination contracts still to be implemented together with additional sales to be generated from the recent opening of our new sterilisation facilities in Ireland and China, we are pleased to confirm that the business is on track for a successful year.”

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->